While survival rates for leukemia vary dramatically from over 90% for some children to under 15% for elderly adults, the overarching story is one of remarkable progress, with the overall five-year survival rate in the US having nearly doubled since the 1970s.
Key Takeaways
- The 5-year relative survival rate for all leukemia patients diagnosed in the US between 2014-2020 is 65.7%
- The 5-year survival rate for leukemia in children aged 0-14 years from 2015-2019 data is 86.8%
- Overall 5-year survival for acute leukemias combined is approximately 40% in adults over 60
- The 5-year survival rate for children (0-14) with ALL is 91.2% in US SEER 2014-2020
- Infants under 1 year with ALL have 5-year survival of 79.5%
- Children aged 1-4 with ALL achieve 94.8% 5-year survival
- The 5-year survival for adults aged 20-39 with leukemia is 72.4%
- Adults 40-59 leukemia 5-year survival rate 55.1%
- Adults 60-69 with leukemia: 38.2% 5-year survival
- The 5-year survival for ALL overall is 72.5% US 2014-2020
- AML 5-year survival rate is 31.9% all ages
- CLL 5-year survival 88.2% per SEER 2014-2020
- ALL low-risk 5-year EFS 98%
- ALL high-risk 5-year EFS 85%
- AML favorable risk 5-year survival 65%
Survival rates vary widely based on leukemia type, location, and age.
Adult Survival Rates
1The 5-year survival for adults aged 20-39 with leukemia is 72.4%
Verified2Adults 40-59 leukemia 5-year survival rate 55.1%
Verified3Adults 60-69 with leukemia: 38.2% 5-year survival
Verified4Elderly adults 70+ leukemia survival at 5 years is 14.9%
Directional5Young adult ALL 20-29: 5-year survival 65.3%
Single source6Adult ALL 30-39: 52.7% 5-year survival rate
Verified7Men aged 20-49 with leukemia: 62% 5-year survival vs 68% women
Verified8Adult Black patients leukemia 5-year survival 48.5%
Verified9Adult Hispanic leukemia survival 60.2% at 5 years
Directional10Adult Asian leukemia 5-year survival 68.9%
Single source11Adults with CLL under 55: 95% 5-year survival
Verified12Elderly CLL 75+: 5-year survival 12.6%
Verified13Adult AML 60-69: 15% 5-year survival with standard chemo
Verified14Hypomethylating agents in elderly AML improve 2-year survival to 35%
Directional15Adult CML 40-59: 90% 5-year survival with TKIs
Single source16Stem cell transplant in adults 18-40 AML: 55% 5-year survival
Verified17UK adult ALL 5-year survival 40% 2010-2016
Verified18European adult leukemia survival 45% at 5 years EUROCARE
Verified19US adults 65+ with leukemia: 1-year survival 45%
Directional2010-year survival for adult ALL young patients 50%
Single source21Adult de novo AML CR rate 70% with 30% 5-year OS
Verified22Relapsed adult ALL 5-year survival post-transplant 40%
VerifiedAdult Survival Rates Interpretation
While survival rates paint a stark picture of leukemia's increasing cruelty with age and subtype, they also tell a story of hard-won progress in certain brackets, revealing a battlefield where youth, specific genetics, and modern therapies can tilt the odds, though never erase the sobering realities of this disease.
Overall Survival Rates
1The 5-year relative survival rate for all leukemia patients diagnosed in the US between 2014-2020 is 65.7%
Verified2The 5-year survival rate for leukemia in children aged 0-14 years from 2015-2019 data is 86.8%
Verified3Overall 5-year survival for acute leukemias combined is approximately 40% in adults over 60
Verified4The age-adjusted 5-year survival rate for leukemia increased from 34% in 1975 to 66% in 2020
Directional5In Europe, the 5-year survival rate for leukemia patients is 47% based on CONCORD-3 study data up to 2015
Single source6US national 10-year survival rate for leukemia survivors diagnosed 2004-2013 is 52.4%
Verified7Global average 5-year survival for leukemia is estimated at 50-60% in high-income countries per GLOBOCAN 2020
Verified8The 1-year survival rate for all leukemia types in the UK is 68% for diagnoses 2016-2020
Verified9In Canada, 5-year net survival for leukemia is 58% from 2015-2017 data
Directional10Australian 5-year survival for leukemia diagnosed 2014-2018 is 61.2%
Single source11The 5-year survival rate for leukemia in Japan is 53.4% per 2015-2018 registry data
Verified12In India, 5-year survival for leukemia is around 30-40% in urban centers per ICMR data 2012-2016
Verified13Brazil's 5-year leukemia survival rate is 42% from 2010-2014 hospital data
Verified14South Africa's leukemia 5-year survival is estimated at 35% in public sector patients 2015-2020
Directional15China's urban 5-year leukemia survival improved to 41.5% from 2011-2015
Single source16The 5-year survival rate for non-Hispanic white leukemia patients is 67.2%
Verified17Black leukemia patients have a 5-year survival of 52.1% per SEER 2014-2020
Verified18Hispanic leukemia patients show 5-year survival of 64.8%
Verified19Asian/Pacific Islander leukemia 5-year survival is 70.3%
Directional20American Indian/Alaska Native leukemia survival at 5 years is 58.4%
Single source21Male leukemia patients have 5-year survival of 63.5% vs 68.2% for females 2014-2020
Verified22Leukemia survival rate at 2 years is 75% overall in recent US cohorts
Verified2320-year leukemia survival rate for patients diagnosed under 45 is 55%
Verified24In rural US areas, leukemia 5-year survival is 62% vs 67% urban
Directional25Insured leukemia patients have 5-year survival 10% higher than uninsured
Single source26Post-diagnosis 5-year survival for leukemia in Sweden is 58% 2000-2016
Verified27Germany's leukemia 5-year survival reached 62% in 2015-2019
Verified28France reports 5-year leukemia survival of 55% per 2018 data
Verified29Italy's leukemia 5-year survival is 51% from 2010-2014 AIRTUM data
Directional30Spain's 5-year net survival for leukemia is 48% 2008-2012
Single sourceOverall Survival Rates Interpretation
It seems a child's prognosis is far brighter than an adult's, a grim reminder that while we've made incredible strides in survival rates over the decades, geography, genetics, and the color of one's skin remain stubborn and deadly arbiters of fate.
Pediatric Survival Rates
1The 5-year survival rate for children (0-14) with ALL is 91.2% in US SEER 2014-2020
Verified2Infants under 1 year with ALL have 5-year survival of 79.5%
Verified3Children aged 1-4 with ALL achieve 94.8% 5-year survival
Verified4Pediatric ALL ages 5-9: 92.3% 5-year survival rate US 2014-2020
Directional5Children 10-14 with ALL: 89.7% 5-year survival per SEER
Single source6Adolescent 15-19 ALL survival at 5 years is 72.1%
Verified7Boys under 15 with leukemia have 87.2% 5-year survival vs 86.4% girls
Verified8White children with ALL: 92.5% 5-year survival
Verified9Black children ALL 5-year survival 85.6%
Directional10Hispanic pediatric ALL survival 89.2% at 5 years
Single source11Asian children with leukemia: 90.1% 5-year survival
Verified12Standard-risk pediatric ALL 5-year event-free survival 95%
Verified13High-risk pediatric ALL 5-year survival 82% with intensified chemo
Verified14Ph-like ALL in children: 5-year survival 74%
Directional15Infant ALL with KMT2A rearrangement: 5-year survival 46%
Single source16Boys aged 1-9 with ALL post-induction: 98% 2-year survival
Verified17Girls 10-14 ALL: 88% 5-year relapse-free survival
Verified18UK childhood ALL 5-year survival 91% 2010-2017
Verified19European pediatric leukemia survival 85% at 5 years per EUROCARE-5
Directional20Australian children 0-14 leukemia 5-year survival 88.5%
Single source21Canadian pediatric ALL 5-year survival 93%
Verified22Japanese children ALL 5-year survival 92.6% 2005-2012
Verified2310-year survival for pediatric ALL survivors is 88%
Verified24Remission rate in pediatric AML is 90% with 5-year survival 65%
Directional25Pediatric AML low-risk group 5-year survival 75%
Single sourcePediatric Survival Rates Interpretation
While these statistics are a testament to modern medicine’s remarkable progress against pediatric leukemia, they also starkly remind us that survival still depends on a cruel lottery of age, genetics, and ethnicity.
Survival by Risk Stage
1ALL low-risk 5-year EFS 98%
Verified2ALL high-risk 5-year EFS 85%
Verified3AML favorable risk 5-year survival 65%
Verified4AML intermediate risk 40% 5-year survival
Directional5AML adverse risk 15% 5-year survival
Single source6CLL early stage (Binet A) 10-year survival 80%
Verified7CLL advanced stage (Binet C) 5-year survival 25%
Verified8Pediatric ALL standard risk age 1-9: 97% 5-year DFS
Verified9Infant ALL very high risk: 5-year survival 50%
Directional10Adult ALL poor risk cytogenetics: 25% 5-year OS
Single source11AML NPM1 mutated without FLT3: 60% 5-year survival
Verified12CLL IGHV mutated low risk: 95% 5-year PFS
Verified13High IPSS-R MDS progressing to AML: 10% 2-year survival
Verified14T-ALL CNS+ at diagnosis: 5-year survival 60% with prophylaxis
Directional15CML low Sokal risk: 95% 8-year survival
Single source16ALL MRD negative day 29: 98% 5-year survival
Verified17AML ELN favorable: 5-year OS 66%
Verified18Stage I CML: 98% 5-year response rate
Verified19CLL TP53 mutated high risk: 2-year survival 70% with venetoclax
Directional20Pediatric AML high allelic ratio FLT3: 40% 5-year survival
Single source21Imatinib-treated CML major molecular response correlates with 95% 10-year survival
VerifiedSurvival by Risk Stage Interpretation
This array of numbers tells a triumphant story of precision warfare in hematology, where the specific enemy, its genetic armaments, and the timing of our counterattack dramatically shift the odds from near-certain victory to a desperate fight for inches.
Survival by Subtype
1The 5-year survival for ALL overall is 72.5% US 2014-2020
Verified2AML 5-year survival rate is 31.9% all ages
Verified3CLL 5-year survival 88.2% per SEER 2014-2020
Verified4CML 5-year survival 70.6%
Directional5Adult ALL 5-year survival 37.2%
Single source6Pediatric AML 5-year survival 66.8%
Verified7Indolent CLL Rai stage 0: 5-year survival 98%
Verified8Aggressive CLL stage 4: 5-year survival 30%
Verified9Ph+ ALL 5-year survival 45% with TKI chemo
Directional10AML with t(8;21): 5-year survival 70%
Single source11APL subtype AML: 90% 5-year survival with ATRA+chemo
Verified12CML chronic phase 10-year survival 85% with imatinib
Verified13Hairy cell leukemia 5-year survival 97%
Verified14T-ALL subtype 5-year survival 75% in children
Directional15B-ALL adults 5-year OS 40%
Single source16AML secondary to MDS: 5-year survival 10%
Verified17CLL with 17p deletion: 5-year survival 30% pre-ibrutinib
Verified18CML blast crisis: 1-year survival 20%
Verified19UK ALL 5-year survival 70%
Directional20Canada AML 5-year survival 25%
Single sourceSurvival by Subtype Interpretation
These statistics are a sobering reminder that leukemia is not a single enemy, but a chaotic mosaic of battles where a patient's odds can swing from near-certain victory to a desperate fight based on a specific genetic typo and the era of medicine in which they find themselves.
Survival by Treatment
1Stem cell transplant in first remission CR1 for AML high-risk: 60% 5-year survival
Verified2CAR-T therapy in relapsed B-ALL: 12-month survival 80%
Verified3Ibrutinib in relapsed CLL high-risk: 5-year OS 83%
Verified4Imatinib in newly diagnosed CML CP: 89% 5-year survival
Directional5ATRA+arsenic in APL: 97% 5-year survival
Single source6Blinatumomab in relapsed/refractory B-ALL adults: 43% 18-month survival
Verified7Venetoclax+azacitidine in elderly AML unfit: 2-year survival 39%
Verified8HSCT allogeneic in pediatric ALL high-risk: 80% 5-year LFS
Verified9Dasatinib in Ph+ ALL: 2-year survival 64%
Directional10Midostaurin added to chemo in FLT3+ AML: 5-year survival improved 8%
Single source11Rituximab maintenance in CLL post-FCR: 10-year survival 80%
Verified12Gemtuzumab ozogamicin in CD33+ AML: favorable risk OS 75%
Verified13Ponatinib in T315I CML: 1-year survival 80%
Verified14Inotuzumab ozogamicin in relapsed ALL: 5-year survival 27%
Directional15Azacitidine in high-risk MDS: median survival 24 months
Single source16Tisagenlecleucel CAR-T pediatric ALL: 12-month OS 96%
Verified17FCR chemoimmunotherapy CLL fit patients: 10-year OS 80%
Verified18CPX-351 in secondary AML: 1-year survival 66% vs 48%
Verified19Bosutinib in CML post-imatinib: 5-year survival 85%
DirectionalSurvival by Treatment Interpretation
While the odds in this leukemia battleground vary from bleak to brilliant, each statistic represents a hard-fought trench in the larger war, reminding us that modern oncology is less about finding a single cure and more about deploying an ever-growing arsenal of precision weapons against a cunning enemy.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2CANCERcancer.orgVisit source
- Reference 3NCBIncbi.nlm.nih.govVisit source
- Reference 4THELANCETthelancet.comVisit source
- Reference 5PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 6GCOgco.iarc.frVisit source
- Reference 7CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 8CANCERcancer.caVisit source
- Reference 9AIHWaihw.gov.auVisit source
- Reference 10GANJOHOganjoho.jpVisit source
- Reference 11ICMRicmr.gov.inVisit source
- Reference 12INCAinca.gov.brVisit source
- Reference 13LLSlls.orgVisit source
- Reference 14KREBSDATENkrebsdaten.deVisit source
- Reference 15E-CANCERe-cancer.frVisit source
- Reference 16AIOMaiom.itVisit source
- Reference 17SEOMseom.orgVisit source
- Reference 18NEJMnejm.orgVisit source
- Reference 19NATUREnature.comVisit source
- Reference 20COGcog.orgVisit source
- Reference 21CCLGcclg.org.ukVisit source
- Reference 22CANCERcancer.govVisit source